LORCASERIN HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LORCASERIN HYDROCHLORIDE (LORCASERIN HYDROCHLORIDE).
Selective serotonin 2C (5-HT2C) receptor agonist; modulates pro-opiomelanocortin (POMC) neurons, reducing appetite and increasing satiety.
| Metabolism | Primarily metabolized by CYP2D6; also metabolized by CYP3A4, CYP1A2, and CYP2C19. |
| Excretion | Approximately 66% of the total radiolabeled dose is excreted in urine (including ~4% unchanged drug) and ~21% in feces, with the remainder as metabolites. |
| Half-life | Mean terminal elimination half-life is 11 hours (range 9–14 hours) in healthy subjects; steady-state is reached within 3 days. |
| Protein binding | Approximately 70% bound to human plasma proteins, primarily albumin. |
| Volume of Distribution | Mean apparent volume of distribution (Vd/F) is approximately 195 L (2.4 L/kg for a 70 kg individual), indicating extensive tissue distribution. |
| Bioavailability | Absolute oral bioavailability is approximately 100%; no significant first-pass metabolism. |
| Onset of Action | Not applicable for oral route; no immediate clinical effect. Therapeutic weight loss effects are typically observed after 4–12 weeks of treatment. |
| Duration of Action | Dosing is twice daily; continuous serotonergic effect sustained throughout the day with consistent pharmacokinetics. Clinical benefit requires long-term administration. |
10 mg orally twice daily; may increase to 20 mg twice daily if inadequate weight loss after 12 weeks.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; not recommended in end-stage renal disease. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: not recommended; Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dosage adjustment; use with caution due to increased sensitivity and limited data in patients >65 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LORCASERIN HYDROCHLORIDE (LORCASERIN HYDROCHLORIDE).
| Breastfeeding | Not recommended for use during breastfeeding. No adequate data on human milk excretion. Potential for adverse effects in nursing infant based on drug mechanism. Estimated M/P ratio unknown. Advise against breastfeeding during therapy. |
| Teratogenic Risk | Pregnancy Category X. Studies in animals and humans have demonstrated fetal abnormalities. There is no indication for use in pregnancy due to risk of fetal malformations, particularly during first trimester. Contraindicated in pregnancy. |
■ FDA Black Box Warning
WARNING: SEROTONIN SYNDROME OR NEUROLEPTIC MALIGNANT SYNDROME-LIKE REACTIONS. Concomitant use with serotonergic drugs or antipsychotics may cause life-threatening serotonin syndrome or NMS-like reactions. Monitor patients for symptoms (e.g., agitation, hyperthermia, diaphoresis, hypertonia) and discontinue immediately if suspected.
| Serious Effects |
["Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation.","Concomitant use with other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, bupropion, linezolid, methylene blue).","History of serotonin syndrome or neuroleptic malignant syndrome.","Severe hepatic impairment (Child-Pugh >9).","History of pulmonary hypertension (PH) or valvular heart disease."]
| Precautions | ["Serotonin syndrome risk; avoid coadministration with other serotonergic agents.","Monitor for serotonin syndrome or NMS-like reactions particularly during initiation or dose increases.","Risk of hypoglycemia in patients with type 2 diabetes; monitor blood glucose.","May cause euphoria, depression, or suicidal thoughts; discontinue if symptoms occur.","Controlled substance (Schedule IV) due to abuse potential.","May impair cognitive function; caution when driving or operating machinery.","Use with caution in patients with hepatic impairment; avoid in severe hepatic impairment.","Hypersensitivity reactions including angioedema and anaphylaxis have been reported.","Potential for priapism; instruct patients to seek emergency care if erection lasts >4 hours.","Avoid use in patients with history of pulmonary hypertension; monitor for dyspnea, chest pain, or edema."] |
Loading safety data…
| Fetal Monitoring |
| Regular monitoring of cardiac valvulopathy (echocardiograms) due to potential for serotonergic cardiac effects; monitor for symptoms of serotonin syndrome; perform pregnancy testing prior to initiation and periodically during treatment. |
| Fertility Effects | In animal studies, lorcaserin decreased fertility indices at high doses. Human data limited; potential for reversible impairment of spermatogenesis or ovulation. Advise patients of possible effects on reproductive function. |